Theme: Diabetes from Monitoring to Management

Diabetes Meeting 2017

Diabetes Meeting 2017

About Conference

Being recognized as a world-renowned organization, Conference Series LLC takes pride to introduce the commencement of “22nd International Congress on Prevention of Diabetes and Complications" from October 05-06, 2017 at London, UK. The conference aims to provide an opportunity to share knowledge, expertise along with unparalleled networking opportunities between a large number of medical and industrial professionals in this sphere. Conference series LLC’s Diabetes Meeting 2017 conference gathers renowned scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine under a single roof where networking and global partnering happens for the acceleration of future research.

Conference series LLC through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. Conference series LLC hosts over 400 leading-edge peer reviewed Open Access journals and has organized over 300 scientific conferences all over the world.

Conference Series LLC welcomes all the scientists, physicians, surgeons, young researchers, industrial delegates and talented student communities in the field of diabetic medicine to attend this Diabetes Conferences, where all the aspects of diabetes will be discussed under single roof. Diabetes Meeting 2017 will be an excellent amalgamation of academia and industry as it involves every aspects of empirical and conceptual thinking in exploring new dimensions in this field.  It is open to all types of research methodologies both from academia and industry.

Diabetes Meeting 2017 is an international platform for presenting research about “Diabetes from monitoring to management” exchanging ideas about it and thus, contributes to the dissemination of knowledge in management of the disease for the benefit of the society. Diabetes Meeting 2017 is where the future of management and novel therapeutics for the disease intersects.

Why to Attend?

The meeting will provide many opportunities to network and discuss science and medicine, ensure equity of opportunity, find new funding and research opportunities, and build collaborations and contacts with international colleagues. We are sure that you will find this to be a truly exciting meeting presenting both the breadth and depth of clinical and basic research.  Trade partners will have exposure to more areas of specialties in Diabetes and Endocrinology. World Class Speakers and Fresh New Talent from across the Globe in Health Industry gather in this world congress.

Target Audience

  • Diabetologists
  • Endocrinologists
  • Doctors
  • Researchers
  • Physicians
  • Business Professionals
  • Academic Professionals
  • Students
  • Scientists
  • Medical and Pharma Companies
  • Medical Colleges and Hospitals
  • Diabetes Societies and Associations





Sessions/Tracks

Track 1: Physiology of Diabetes

Diabetes is one of the most significant global health concerns of modern times. The causes of type 2 diabetes are multi-factorial and include both genetic and environmental elements that affect beta-cell function and tissue (muscle, liver, adipose tissue, and pancreas) insulin sensitivity. A number of factors have been suggested as possibly linking insulin resistance and beta-cell dysfunction in the pathogenesis of Type 2 Diabetes. A majority of individuals suffering from type 2 diabetes are obese, with central visceral adiposity. According to the International Diabetes Federation, diabetes statistics says that there are more than 317 million people have been diagnosed with diabetes, and an additional 187 million are living undiagnosed. The global revenue earned from drugs sales to treat Type 2 Diabetes was approximately $36.89 billion in 2012 that is rapidly increasing in incidence and prevalence across the globe predicated to elevate this figure to approximately $68.42 billion by 2017. Patients with this disease cannot use glucose properly for their body needs. Latest research on Diabetes has led to the better living of the diabetic patients. In addition to this, self-monitoring of Blood glucose levels, lifestyle modifications and health eating habits are crucial in combating the critical manifestations of this disease which may require proper diabetic nursing. This may also include considerable amount of time educating patients and families on proper dietary, exercise and lifestyle habits to keep symptoms under control.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

American Diabetes Association (USA), Diabetic Association of India (India), Saudi Diabetes and Endocrine Association (Saudi Arabia), Nepal Diabetic Society (Nepal), Australian Diabetes Society (Australia), Diabetes Technology Society (USA), Diabetes Australia (Australia), Austrian Diabetes Association (Austria),  Finnish Diabetes Association (Finland), Association of Juvenile Diabetes (USA)

Track 2: Reverse Diabetes

Reversing diabetes is a term used to describe interventions that reduce dependency on type 2 diabetes medications, effectively reversing the progression of the illness. With time and dedication, type 2 diabetes can be reversed and the results can be very rewarding with less tiredness and better all round health. Loss of body weight can be particularly beneficial in helping to reverse the progression of diabetes. In some cases, people may find they are able to come off medication, although blood sugar levels should be checked regularly as reversing progression of diabetes is not a cure.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)

Track 3: Diabetes and its Complications

With rising numbers of diagnosed diabetics, pharmaceutical manufacturers have capitalized on the burgeoning market for diabetes therapies. Manufacturers' efforts to develop non-invasive methods of insulin delivery are set to revolutionize the insulin therapy market, while demand for oral medications is on the upswing due to a growing Type 2 diabetic population and introduction of technologically advanced therapies for battling complications associated to Type 2 Diabetes like the most prevalent Diabetes Cardiomyopathy. With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells. This will certainly help people recover the prognosis of the fatal disease like diabetes.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Netherlands Diabetes Association (Netherlands), Diabetes New Zealand (New Zealand), Norwegian Diabetes Association (Norway), Diabetes Philippines (Philippines), Polish Diabetes Association (Poland), Diabetic Association of Portugal (Portugal), Diabetic Society of Singapore (Singapore), Diabetes South Africa (South Africa), Spanish Diabetes Society (Spain), Swedish Diabetes Association (Sweden)

Track 4: Diabetes Medications & Pharmacotherapy

The global diabetes treatment market is undergoing significant transition driven by the advent of new analytical technologies and developments in diabetes treatment. There has been a drastic increase in the incidents of diabetes worldwide, owing to the rising level of lifestyles and obesity in global population. The diabetes treatment products include injectable diabetes drugs, oral drugs, insulin therapies, insulin pumps, insulin injection devices and blood glucose monitoring systems which eliminates the risk of reverse diabetes. According to the new report the world market for diabetes medications will reach $55.3bn in 2017. The anti-diabetic medicines industry generated $35.6bn in 2012, and its revenues will show strong growth to 2023. Monitoring glucose levels is critical for the management of diabetes and new and improved portable, less costly, easy-to-use, accurate and virtually painless blood glucose monitoring systems are now available to take control of the disease.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy;  23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

American Diabetes Association (USA), Diabetic Association of India (India), Saudi Diabetes and Endocrine Association (Saudi Arabia), Nepal Diabetic Society (Nepal), Australian Diabetes Society (Australia), Diabetes Technology Society (USA), Diabetes Australia (Australia), Austrian Diabetes Association (Austria),  Finnish Diabetes Association (Finland), Association of Juvenile Diabetes (USA)

Track 5: Alternative Therapies for Diabetes

Diabetes Mellitus is a dreadful disease and is found in all parts of the world, becoming a serious threat of mankind health. There are lots of chemical agents available to take control on the disease, but total recovery from diabetes is the question to the treatment. Alternative to these synthetic agents, natural cure by plants provides a potential source curing complications of hypoglycemia and reverse Diabetes are widely used in several traditional systems of medicine to prevent prediabetes. Other alternative therapies such as diabetic supplements, acupuncture, hydrotherapy, and yoga therapies are reported to have less likely side effects of conventional approaches for diabetes.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy;  3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)

Track 6: Diabetes Market & Business Analysis

Diabetes has increasingly become a lifestyle-related disease as it afflicts young and old. As the number of patients grows across the globe, there has never been a stronger and more urgent need for novel therapeutic measures in clinical and preclinical evaluation, that arrest the growth of the disease. The diabetes market, consisting mainly of Type 1 and Type 2 diabetes, is large and growing significantly. The global market value for diabetes therapies and diagnostics has reached to $48.5 billion. The largest segment of the market, insulin products, is worth $20.8 billion in the recent times, including administration and diagnostic devices. Monitoring devices and other related equipment, the second-largest market is established with an investment of $13.5 billion in which was proposed for $11.3. The fastest-growing segment of oral diabetic complication of hypoglycemia drugs manufacturing funding is $14.13 in present scenario of diabetes market.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Netherlands Diabetes Association (Netherlands), Diabetes New Zealand (New Zealand), Norwegian Diabetes Association (Norway), Diabetes Philippines (Philippines), Polish Diabetes Association (Poland), Diabetic Association of Portugal (Portugal), Diabetic Society of Singapore (Singapore), Diabetes South Africa (South Africa), Spanish Diabetes Society (Spain), Swedish Diabetes Association (Sweden)

Track 7: Nutrition Therapy of Diabetes

With the growing awareness and information regarding preventive measures for combating fatal disease like diabetes, consumers are opting for proper food along with medicines. One can improve the health in a big way by making small changes to the diet, while still enjoying the favourite foods and taking pleasure from the meals. A diabetes diet is simply a healthy eating plan that is high in nutrients, low in fat, and moderate in calories. Manufacturers are now keen towards Diabetes Nutrition on introducing new low calorie food products with sugar substitutes and less oil, in view of the increasing consumer interest toward healthy eating and help prevent diabetes and its concomitant risk factors.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

American Diabetes Association (USA), Diabetic Association of India (India), Saudi Diabetes and Endocrine Association (Saudi Arabia), Nepal Diabetic Society (Nepal), Australian Diabetes Society (Australia), Diabetes Technology Society (USA), Diabetes Australia (Australia), Austrian Diabetes Association (Austria),  Finnish Diabetes Association (Finland), Association of Juvenile Diabetes (USA)

Track 8: Diabetes Cholesterol

Diabetes mellitus type 2, formerly noninsulin-dependent diabetes mellitus is a metabolic disorder that is characterized by hyperglycaemia (high blood sugar) in the context of insulin resistance and relative lack of insulin.In type 2 diabetes, the cells in your child's body don’t respond to the insulin, and glucose builds up in her bloodstream. This is called insulin resistance. This could lead to other conditions in the future, like heart disease, blindness, and kidney failure.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)

Track 9: Diabetes, Metabolism and Obesity

The original description of the metabolic syndrome by Reaven, consisted of obesity, insulin resistance, hypertension, impaired glucose tolerance or diabetes, hyperinsulinemia and dyslipidemia characterized by elevated triglyceride, and low HDL concentrations. All of the features described above are risk factors for atherosclerosis, and thus, metabolic syndrome constituted a significant risk for coronary heart disease. The features of obesity/overweight and insulin resistance also provided a significant risk for developing type 2 diabetes. The risks for coronary heart disease and diabetes with metabolic syndrome are greater than those for simple obesity alone, and therefore, an understanding of the pathogenesis and through it, a rational approach to its therapy are of prime importance. As our understanding of the action of insulin evolves to comprehensively include the recent discoveries, we can better see that insulin resistance is the basis of most if not all of the features of this syndrome. The original conceptualization of this syndrome was on the basis of resistance to the metabolic actions of insulin. Thus, hyperinsulinemia, glucose intolerance, type 2 diabetes, hypertriglyceridemia, and low HDL concentrations could be accounted for by resistance to the actions of insulin on carbohydrate and lipid metabolism. Although the features described above would to some extent explain the atherogenesis, Reaven has maintained that hyperinsulinemia itself contributes to atherogenicity, and thus, insulin is atherogenic, leading to the coronary heart disease and cerebrovascular disease associated with this syndrome.

Obesity probably leads to hypertension through increased vascular tone created by a reduced bioavailability of NO because of increased oxidative stress, increased asymmetric dimethylarginine (ADMA) concentrations, increased sympathetic tone, and increased expression of angiotensinogen by adipose tissue leading to an activation of the renin-angiotensin system. The last of these factors requires further critical investigation.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Netherlands Diabetes Association (Netherlands), Diabetes New Zealand (New Zealand), Norwegian Diabetes Association (Norway), Diabetes Philippines (Philippines), Polish Diabetes Association (Poland), Diabetic Association of Portugal (Portugal), Diabetic Society of Singapore (Singapore), Diabetes South Africa (South Africa), Spanish Diabetes Society (Spain), Swedish Diabetes Association (Sweden)

Track 10: Depression in Patients with Diabetes

Diabetes patients with depression symptoms were less likely to be at their glucose goal (43% vs 50%; P = .0176) but more likely to be at their blood pressure goal (57% vs 51%; P = .0435). The association between lipids and depression symptoms was related to a lower rate for low-density lipoprotein testing (56% vs 68%; P < .0001). Treatment with antidepressants resulted in a greater percentage achieving glucose and blood pressure goals but not lipid goals. Depression seems to have a variable impact on achieving these clinical goals, perhaps because the goals have differing measurement logistics and biological profiles. Further research is needed to learn whether better treatment of depressive symptoms leads to improvements in meeting diabetes clinical goals.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy;  3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)

Track 11: Case Reports and Others

Diabetes case reports are in-depth inquiries of an individual, crowd, occasion or public. The data are assembled from a diversity of places by various methods. The case study technique encompasses spotting what happens to, or reconstructing ‘the case history’ of a single participant or group of individuals, i.e. the idiographic approach. Case studies permits an investigator to investigate a topic in far more detailed and minute way. The case study is not itself a research method, but investigators choose methods of data collection and analysis that will generate material suitable for case studies. Most of this evidence is likely to be qualitative but the psychologist might collect numerical data as well and present in various diabetes conference and scientific sessions

Type 1 diabetes

Type 2 diabetes

Latent autoimmune diabetes of adults (LADA)

Preclinical safety evaluation of stem cell-based therapies for diabetes

Diabetes in culturally Diverse Populations: From Biology to Culture

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

American Diabetes Association (USA), Diabetic Association of India (India), Saudi Diabetes and Endocrine Association (Saudi Arabia), Nepal Diabetic Society (Nepal), Australian Diabetes Society (Australia), Diabetes Technology Society (USA), Diabetes Australia (Australia), Austrian Diabetes Association (Austria),  Finnish Diabetes Association (Finland), Association of Juvenile Diabetes (USA)

Track 12: Diabetes Tests and Diagnosis

Tests for type 1 and type 2 diabetes and prediabetes : 

Glycated hemoglobin (A1C) test: This blood test indicates your average blood sugar level for the past two to three months. It measures the percentage of blood sugar attached to hemoglobin, the oxygen-carrying protein in red blood cells. The higher your blood sugar levels, the more hemoglobin you'll have with sugar attached. An A1C level of 6.5 percent or higher on two separate tests indicates that you have diabetes. An A1C between 5.7 and 6.4 percent indicates pre-diabetes. Below 5.7 is considered normal.

If the A1C test results aren't consistent, the test isn't available, or if you have certain conditions that can make the A1C test inaccurate — such as if you're pregnant or have an uncommon form of hemoglobin (known as a hemoglobin variant) — your doctor may use the following tests to diagnose diabetes:

Random blood sugar test: A blood sample will be taken at a random time. Regardless of when you last ate, a random blood sugar level of 200 milligrams per deciliter (mg/dL) — 11.1 millimoles per liter (mmol/L) — or higher suggests diabetes.

Fasting blood sugar test. A blood sample will be taken after an overnight fast. A fasting blood sugar level less than 100 mg/dL (5.6 mmol/L) is normal. A fasting blood sugar level from 100 to 125 mg/dL (5.6 to 6.9 mmol/L) is considered prediabetes. If it's 126 mg/dL (7 mmol/L) or higher on two separate tests, you have diabetes.

Oral glucose tolerance test:  For this test, you fast overnight, and the fasting blood sugar level is measured. Then you drink a sugary liquid, and blood sugar levels are tested periodically for the next two hours. A blood sugar level less than 140 mg/dL (7.8 mmol/L) is normal. A reading of more than 200 mg/dL (11.1 mmol/L) after two hours indicates diabetes. A reading between 140 and 199 mg/dL (7.8 mmol/L and 11.0 mmol/L) indicates pre-diabetes.

Tests for gestational diabetes:

Initial glucose challenge test: This will be begin the glucose challenge test by drinking a syrupy glucose solution. One hour later, you'll have a blood test to measure your blood sugar level. A blood sugar level below 140 mg/dL (7.2 to 7.8 mmol/L) is usually considered normal on a glucose challenge test, although this may vary at specific clinics or labs. If your blood sugar level is higher than normal, it only means you have a higher risk of gestational diabetes. Your doctor will order a follow-up test to determine if you have gestational diabetes.

Follow-up glucose tolerance testing: For the follow-up test, you'll be asked to fast overnight and then have your fasting blood sugar level measured. Then you'll drink another sweet solution — this one containing a higher concentration of glucose — and your blood sugar level will be checked every hour for a period of three hours. If at least two of the blood sugar readings are higher than the normal values established for each of the three hours of the test, you'll be diagnosed with gestational diabetes.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)

Track 13: Diabetes Retinopathy

Diabetic retinopathy is caused by changes in the blood vessels of the retina. When these blood vessels are damaged, they may leak blood and grow fragile new vessels. When the nerve cells are damaged, vision is impaired. These changes can result in blurring of your vision, hemorrhage into your eye, or, if untreated, retinal detachment. Diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness. People with untreated diabetes are 25 times more at risk for blindness than the general population. The longer a person has had diabetes, the higher the risk of developing diabetic retinopathy. Fortunately, with regular, proper primary eye care and treatment when necessary, the incidence of severe vision loss has been greatly reduced.

  • Diabetic macular edema
  • Mild and moderate nonproliferative retinopathy
  • Severe and proliferative nonproliferative retinopathy
  • Visual acuity testing
  • Tonometry
  • Pupil dilation
  • Optical coherence tomography
  • Anti-VEGF Injection Therapy
  • Focal/grid macular laser surgery
  • Corticosteroids
  • Vitrectomy

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Netherlands Diabetes Association (Netherlands), Diabetes New Zealand (New Zealand), Norwegian Diabetes Association (Norway), Diabetes Philippines (Philippines), Polish Diabetes Association (Poland), Diabetic Association of Portugal (Portugal), Diabetic Society of Singapore (Singapore), Diabetes South Africa (South Africa), Spanish Diabetes Society (Spain), Swedish Diabetes Association (Sweden)

Track 14: Emerging Focus in Diabetes Research

Diabetes throws a light in a growing epidemic imposing thoughtful social economic crisis around the nation. Despite scientific innovations and better healthcare research amenities the disease continues to burden numerous segments, especially middle and low income countries. The current trends designate the rise in premature death, posing a major threat to global development. The advancement in science and technology have observed the expansion of newer generation of nanomedicine in drugs discovery. Then, the documentation and clinical investigation of bioactive ingredients from plants have transformed the investigation on drug discovery and lead identification for diabetes management control.

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

American Diabetes Association (USA), Diabetic Association of India (India), Saudi Diabetes and Endocrine Association (Saudi Arabia), Nepal Diabetic Society (Nepal), Australian Diabetes Society (Australia), Diabetes Technology Society (USA), Diabetes Australia (Australia), Austrian Diabetes Association (Austria),  Finnish Diabetes Association (Finland), Association of Juvenile Diabetes (USA)

Track 15: Diabetes Education and its Risk Factors

Diabetes Education: It includes diabetes education modules. The Diabetes Education Modules (2011) contain more than 800 slides and detailed speaker notes to reflect the objectives contained in the International Curriculum for Health Professionals Education. Health professionals anywhere in the world can adopt this resource to develop diabetes education programmes for other health professionals.

The consistent, evidence-based research and information provided in these materials are designed to help educators gain recognition for their training and assure governments and education organisations that the education programmes they offer are of a high standard.

Risk Factors: The risk factors for type 1 diabetes are still being researched. However, having a family member with type 1 diabetes slightly increases the risk of developing the disease. Environmental factors and exposure to some viral infections have also been linked to the risk of developing type 1 diabetes. Several risk factors have been associated with type 2 diabetes and include:

  • Family history of diabetes
  • Overweight
  • Unhealthy diet           
  • Physical inactivity
  • Increasing age
  • High blood pressure
  • Ethnicity
  • Impaired glucose tolerance (IGT)
  • History of gestational diabetes
  • Poor nutrition during pregnancy

Related Diabetes conferences | Endocrinology ConferencesConferences Series LLC

23rd International Conference on Herbal and Alternative Remedies for Diabetes and Endocrine Disorders, November 2-4, 2017, Bangkok, Thailand; 3rd Global Congress on Endocrine Disorders and Therapies, August 24-25, 2017 Toronto, Canada; 13th World Congress on Diabetes, October 05-06, 2017, London, UK; 16th Global Diabetes Conference & Medicare Expo, March 22-23 2017, Rome Italy; 18th European Diabetes Congress July 17-18, 2017 Lisbon, Portugal; 12th Asia Pacific Diabetes Conference and Expo, July 24-25 2017, Melbourne, Australia; Physiology, pathophysiology and future treatment options for diabetic complications December 7 2015,UK; Endocrinology Conferences October 10-12, 2016 Manchester, UK; ATTD 2017 - Advanced Technologies & Treatments for Diabetes, February 15-18 2017, Paris, France; ICDM 2017:19th International Conference on Diabetes and Metabolism, February 07-08, 2017, Mumbai, India; 19th European Congress Of Endocrinology 2017, May 20-23, Lisbon, Portugal

Related Societies

Estonian Diabetes Association (Estonia), Finnish Diabetes Association (Finland), French Diabetics Association (France), German Diabetes Union, (Germany), Hellenic Diabetes Association (Greece), Hong Kong Diabetes Federation (Hong Kong), Icelandic Diabetic Association (Iceland), Diabetes Federation of Ireland (Ireland), The Diabetes Association (Italy), Japan Diabetes Society (Japan)





Market Analysis

Importance & Scope

Healthcare for London has already identified that much needs to be done to improve the care of people with polygenic disease in London and to bring care up to the national standards to deliver the polygenic disease National Services Framework. The very fact that less than 15 august 1945 of Londoners with diabetes have undertaken structured patient education and a similar proportion are unaware of which type of polygenic disease they need is indicative of the very fact that London has not adequately invested with in polygenic disease care. Polygenic disease uk so welcomes the aid for London programme which we believe will improve prioritisation, investment and organisation of integrated polygenic disease care. Folks with polygenic disease want access to the right skills, within the right place, at the right time through Renaissance man, specialist and social care operating along. We have a tendency to be notably happy that the aid for London model recognises these desires and holds folks with polygenic disease at its heart, in terms of care coming up with and user involvement to deliver supported self-management. The aspirations of the set up are challenging however we have a tendency to believe they will be achieved and appearance forward to tributary to measurable enhancements over future 3 years. The case for ever-changing the means we have a tendency to deliver polygenic disease care within the capital is compelling. There are quite 2 million folks with polygenic disease within the UK1 and prevalence is expected to extend within the future. There are, moreover, vital inequalities within the means polygenic disease is prevented, diagnosed and treated across London. Folks with semi-permanent conditions are the most important users of aid in London and account for eightieth of general practitioner consultations nationally. Disbursal on polygenic disease currently accounts for associate degree calculable 100% of the NHS budget. Healthcare for London aims to dramatically improve access to high-quality polygenic disease take care of all Londoners and to scale back health inequalities within the capital. a brand new model of care and care pathways are developed with aid professionals, folks with polygenic disease and commissioners. It’ll place patients at the centre of care provision. Folks with polygenic disease are supported to self-manage their condition through education programmes, put together in agreement tending plans, and a lot of support and recommendation from trained professionals. A serious goal is to improve interference and early detection of polygenic disease. We have a tendency to also be seeking to forestall complications and supply applicable acute management for folks with polygenic disease. To achieve this we'd like to supply higher education for folks with polygenic disease and training for the hands, with a larger emphasis on self-management. We have a tendency to conjointly ought to higher manage polygenic disease in maternity, in children and adolescents with polygenic disease, and for folks receiving care in inmate settings.

Why London?

There are more than 350,000 people with polygenic disease in London. Polygenic disease is additional common in people of black and south Asian origin. For example, the prevalence of polygenic disease is up to 5 times higher in Pakistani and Bangladeshi people than in Caucasian race. Polygenic disease tends to gift at a younger age in people of black and south Asian descent, and these groups have the next risk of developing diabetes-related long run complications. Generally, London features a higher proportion of black and Asian ethnic groups compared with the remainder of the country. For this reason, London features a higher prevalence of polygenic disease and polygenic disease complications. It’s calculable that around one in four people with polygenic disease in London, about 80,000 people2 , do not understand they need it. These people area unit at important risk of developing semi-permanent complications. There is variation within the level of unknown polygenic disease across London PCTs (figure 1). Around 1/2 folks with polygenic disease have complications at diagnosing, suggesting that they need already had the condition for up to ten years. Unknown polygenic disease, presenting as associate degree acute emergency, contributes to the requirement for unscheduled emergency care and acute admission. Polygenic disease connected accident and emergency (A&E) attendances and hospital admissions considerably impact on secondary care work. Polygenic disease is that the semi-permanent condition that may increase most in terms of prevalence. The quantity of individuals with polygenic disease in London is predicted to extend by up to 2,000 between 2005 and 2025 unless successful blubber bar ways area unit introduced. The rising prevalence of polygenic disease is attributable to associate degree ageing population and unhealthy lifestyles resulting in blubber. This is often a risk issue significantly important for those of Asian or African Caribbean descent. The incidence and prevalence of polygenic disease is rising dramatically, with recent information suggesting a seventy fifth increase within the past seven years. For the primary time in London, additional young girls with polygenic disease United Nations agency become pregnant currently have sort two instead of sort one polygenic disease.

One in 10 people aged between 20 and 79 in England will die of diabetes related conditions. The impact of diabetes on mortality rates in London is significant:

• London has the highest percentage of deaths in England attributable to diabetes for people aged 20-79 years.

• London has higher than average deprivation which is a major risk factor for mortality from diabetes (figure 3).

• Two-thirds of these deaths are premature (aged under 75 years) and therefore represent a significant economic loss to society.

• Almost 12% of all premature deaths in London are attributable to diabetes. Life expectancy is reduced by 25% (five years for males and seven years for females) if diabetes develops at age 55 years, and more if it develops at a younger age.

Market Value on Diabetic Research:

The Type 2 Diabetes Mellitus (T1DM) market across the eight major countries of the US, Canada, France, Germany, Italy, Spain, the UK and Japan will expand from $4.2 billion in 2014 to $7.1 billion by 2021, at a robust Compound Annual Growth Rate (CAGR) of 7.9%, according to business intelligence provider GBI Research.

The type 2 diabetes treatment market in Asia-Pacific (APAC) will rise in value from an estimated $6.5 billion in 2013 to $10.5 billion by 2020, representing a modest Compound Annual Growth Rate (CAGR) of 7.1%, according to business intelligence provider GBI Research.

Over 29.1 million people (9.3 percent) of the U.S. population currently has diabetes, reports the Centers for Disease Control, and it is an epidemic that seems to be growing. Not only is diabetes detrimental to one’s health, but it is also a costly disease to treat. The total estimated cost of diagnosed diabetes in 2012 was $245 billion, according to the ADA, including $176 billion in direct medical costs and $69 billion in reduced productivity.

    





Past Conference Report

Diabetes 2016

The 12th World Congress on Diabetes (Diabetes 2016) convoked by Conference Series LLC during September 29-30, 2016 was successfully held at Holiday Inn Toronto International Airport with a theme “Diabetes from Monitoring to Management” was a great success where eminent keynote speakers from various reputed institutions with their resplendent presence addressed the gathering.

Thanks to all our momentous speakers, conference attendees who contributed towards the successful run of the conference.

Diabetes 2016 witnessed an amalgamation of peerless speakers who enlightened the crowd with their knowledge and confabulated on various new-fangled topics related to the fields of Endocrinology, Diabetes, Pediatrics, and Surgery.

The meeting was carried out through various sessions, in which the discussions were held on the following major scientific tracks:

·         Diabetes and its complications

·         Diabetes Medications & Pharmacotherapy

·         Innovations in Diabetes Care and Management

·         Diabetes, Metabolism and Obesity

·         Palliative Care & Geriatrics

·         Palliative Care & Spiritual Care

·         Palliative Care & End of Life Care

·         Palliative Care & Chronic Diseases

·         Palliative Care & Symptom Management

·         Palliative Care & Oncology

Conference Series LLC is privileged to felicitate Diabetes 2016 Organizing Committee, Chairs & Co-Chairs who supported for the success of this event. Conference Series LLC would like to thank every individual participant for the enormous exquisite response. This inspires us to continue organizing events and conferences for further research in the field of Diabetes.

With the valuable feedback received from the participants of Diabetes 2016, Conference Series LLC is glad to announce the commencement of “22nd International Congress on Prevention of Diabetes and Complications" during October 5-6, 2017 London, UK. We welcome all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of managing diabetes and its concomitant risk factors.

Let us meet again @ Diabetes Meeting 2017


Past Reports  Gallery  



Click here to submit abstract to any of the above topics

sponsor

Want to Differentiate your company from your competitors and broaden your competitive edge?

Use our global platform of 3000+ Global Events

  • 25 Million+ Visitors to our Global website (conferenceseries.com)
  • 20000+ Unique Visitors per conference
  • 60000+ Page views per conference

For customized sponsorship opportunities at our conferences, or to place an ad on our websites, contact at sponsors@conferenceseries.com or call at: +1-650-268-9744

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 05-06, 2017
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity
Poster Opportunity Available

Conferenceseries Destinations


Mail us at

Drop us an email for Program enquiry.
diabetesmeeting@conferenceseries.net
Sponsors / Exhibiting / Advertising.
General Queries.

Highlights from last year’s Convention!

Authorization Policy

By registering for the conference you grant permission to Conferenceseries Ltd to photograph, film or record and use your name, likeness, image, voice and comments and to publish, reproduce, exhibit, distribute, broadcast, edit and/or digitize the resulting images and materials in publications, advertising materials, or in any other form worldwide without compensation. Taking of photographs and/or videotaping during any session is prohibited. Contact us for any queries.